netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Reversing Retinal Degenerative Diseases: We’re One Step Closer

Degenerative disorders affecting the retinal pigment epithelium (RPE), such as age-related macular degeneration and autosomal recessive bestrophinopathy, can ultimately lead to blindness. Some of these life-changing disorders are the result of mutations in a single gene, called BEST1.

Although the genetic defect in BEST1 was identified almost two decades ago, its physiological role—how it does what it does, was unclear. Now, researchers from Columbia University and University of Rochester have used a novel approach to solve this mystery. Today, they published their pioneering study in the journal eLife

RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, of Columbia University, at work in his lab.

The researchers created a “disease-in-a-dish,” meaning that they coaxed skin cells taken from an adult patient first back into an embryonic-like state (called induced pluripotent stem cells, or iPSCs) and then into RPE cells to create a model of retinal degenerative disease. Then they assessed physiological properties of the RPE cells carrying normal or mutated BEST1 via innovative, interdisciplinary approaches to pinpoint the exact role of the BEST1 gene.

The researchers were also able to show that RPE cells that carry the BEST1 gene mutations, which are the same cells that are damaged by degenerative diseases, can have their damage reversed by providing healthy copies of the BEST1 gene (through viral gene supplementation, which uses a specially selected virus to “carry” new genes into the cells).

“Our team provided evidence that autosomal recessive bestrophinopathy is a ‘chloride channelopathy’ and is a treatable disorder,” said RPB Physician-Scientist Awardee Stephen H. Tsang, MD, PhD, Associate Professor of Ophthalmology and Associate Professor of Pathology and Cell Biology at Columbia University, and Tingting Yang, PhD, Assistant Professor of Pharmacology and Physiology at University of Rochester.

 

 

Related News: Feature Story, Gene Therapy, Macular Degeneration, Retina Disorders , Stem Cell Therapy, Top Story

Four RPB-supported researchers and a Scientific Advisory Panel member have been honored with the prestigious 2018 António Champalimaud Vision Award for their groundbreaking research

Four RPB-supported researchers and a Scientific Advisory Panel member have been honored with the prestigious 2018 António Champalimaud Vision Award for their groundbreaking research

Read More

 

IN THE FUTURE, ALZHEIMER’S MAY BE PREDICTED DURING EYE EXAMS

RPB-funded researchers at Washington University School of Medicine in St. Louis (WUSTL) have found a correlation in 30 older patients between retina thinning and elevated levels of tau and amyloid proteins that are the hallmark of Alzheimer’s disease.

Read More

 

Research to Prevent Blindness and Association of University Professors of Ophthalmology Announce 2018 Recipient of RPB David F. Weeks Award for Outstanding AMD Research

RPB and AUPO announce 2018 recipient of David F. Weeks Award for outstanding AMD research.

Read More

 

Groundbreaking Gene Therapy for Retinal Disease

The first patient receives an FDA-approved gene therapy for inherited retinal disease at Mass. Eye and Ear.

Read More

 

RPB and AAO Award Grants for Big Data Research to Advance Patient Care

Award recipients to use IRIS Registry database to conduct population-based studies.

Read More

 

Research to Prevent Blindness Expands Grants Program

Many of the organization’s individual grants will now be open to researchers at any U.S. academic medical center.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.